Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is trading

<< Previous

Bullboard Posts

Next >>

Comment by SunsetGrillon Mar 11, 2021 9:46am

118 Views

Post# 32771432

RE:RE:RE:RE:RE:RE:RE:RE:This is trading

Well OBVIOUSLY thats what I meant - that takeouts NEVER happen before P III complettion - Cmon read between the lines just a little teeny bit.

Its hightly unlikely (and you cant hope for) a buyout prior to phase III competion (hows that !!)

WalkOverTheStrt wrote: @Sunset - inccorect. BP has done this in the past for mid to later stage biotechs for $1b +

here is a few from five minutes of google seach

PH1 for over $1B
https://www.biopharmadive.com/news/merck-pandion-deal-negotiations-pricey-buyout/596216/

PH2 buyout $1.9B https://www.biopharmadive.com/news/amgen-five-prime-cancer-drug-deal-acquisition/596124/

That drug, bemarituzumab, has been through a phase 2 trial as a front-line treatment in patients with advanced gastric and gastroesophageal junction cancers, with make-or-break data out last November.

https://www.evaluate.com/vantage/articles/data-insights/ma/following-ma-money-phase-and-therapy-area